Figure 3.
Changes in surface PD-L1 expression on BM cells during treatment. (A) This plot represents the mean (circles) and 90% CIs (error bars) for surface PD-L1 (CD274) abundance (MESF) at screening and C3D22 on 3 different cell types: granulocytes, monocytes, and tumor blasts. PD-L1 is notably higher at C3D22 compared with screening on monocytes for Arm A patients because the CIs are not overlapping. (B) This plot represents the mean (circles) and 90% CIs (error bars) of the C3D22 minus screening values for patients who had both time points measured. In this plot, we also observed that PD-L1 has an increased density on monocytes for Arm A patients because the CIs do not span the dashed line at zero. However, PD-L1 on tumor cells is not increased beyond the CI in either plot. Combo, combination therapy; Mono, monotherapy.

Changes in surface PD-L1 expression on BM cells during treatment. (A) This plot represents the mean (circles) and 90% CIs (error bars) for surface PD-L1 (CD274) abundance (MESF) at screening and C3D22 on 3 different cell types: granulocytes, monocytes, and tumor blasts. PD-L1 is notably higher at C3D22 compared with screening on monocytes for Arm A patients because the CIs are not overlapping. (B) This plot represents the mean (circles) and 90% CIs (error bars) of the C3D22 minus screening values for patients who had both time points measured. In this plot, we also observed that PD-L1 has an increased density on monocytes for Arm A patients because the CIs do not span the dashed line at zero. However, PD-L1 on tumor cells is not increased beyond the CI in either plot. Combo, combination therapy; Mono, monotherapy.

Close Modal

or Create an Account

Close Modal
Close Modal